Nexium I.V. Related Published Studies
Well-designed clinical trials related to Nexium I.V. (Esomeprazole)
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. [2008.10]
Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. [2008.09]
Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. [2008.09]
Preoperative administration of esomeprazole has no influence on frequency of refluxes. [2008.05]
The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. [2008.05]
Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. [2008.05]
Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. [2008.04]
Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: A randomized, double-blind, controlled study. [2008.03.28]
Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. [2008.03.15]
Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. [2008.02]
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. [2008.01]
Effect of increasing esomeprazole and pantoprazole doses on Acid control in patients with symptoms of gastro-oesophageal reflux disease : a randomized, dose-response study. [2008]
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. [2007.12]
A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. [2007.12]
Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. [2007.11]
Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. [2007.11]
Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. [2007.10.15]
Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? [2007.09.01]
One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. [2007.09.01]
High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. [2007.09]
Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. [2007.09]
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. [2007.06.15]
Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects. [2007.06]
[Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children] [2007.06]
Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. [2007.06]
One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. [2007.06]
A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. [2007.04]
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. [2007.03]
Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. [2007.02.15]
[Changes of intercellular spaces of esophageal epithelium in patients with gastroesophageal reflux disease before and after esomeprazole treatment] [2007.02.06]
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. [2007.02]
Does esomeprazole prevent post-operative nausea and vomiting? [2007.02]
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. [2007.01.15]
Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. [2007.01]
Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. [2007]
Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects. [2007]
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. [2007]
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. [2007]
Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. [2006.11]
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. [2006.09.01]
Esomeprazole versus pantoprazole for healing erosive oesophagitis. [2006.09]
Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. [2006.09]
Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. [2006.09]
Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. [2006.09]
Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. [2006.07]
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. [2006.07]
Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. [2006.05.15]
Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. [2006.05]
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. [2006.05]
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. [2006.05]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. [2006.04.01]
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. [2006.04]
Esomeprazole for the prevention of postoperative nausea and vomiting. A randomized, placebo-controlled trial. [2006.04]
[Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 months of treatment with Nexium On-Demand Treatment or Nexium continuous treatment. An open, randomised multi-center study] [2006.03.29]
Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. [2006.03]
Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. [2006.03]
Treatment of chronic posterior laryngitis with esomeprazole. [2006.02]
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. [2006.02]
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. [2006.02]
Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. [2006.01]
Pantoprazole 40 mg Is as Effective as Esomeprazole 40 mg to Relieve Symptoms of Gastroesophageal Reflux Disease after 4 Weeks of Treatment and Superior regarding the Prevention of Symptomatic Relapse. [2006]
Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. [2005.12]
Pharmacokinetics of esomeprazole following varying intravenous administration rates. [2005.12]
Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. [2005.02]
Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. [2004.11.15]
Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. [2003.10.01]
Well-designed clinical trials possibly related to Nexium I.V. (Esomeprazole)
Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. [2008.10]
Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. [2008.08]
Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. [2008.08]
The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. [2008.07.04]
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. [2008.07]
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. [2008.07]
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. [2008.06]
The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. [2008.06]
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. [2008.06]
Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience. [2008.06]
Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history. [2008.05.28]
Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? [2008.05.14]
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. [2008.05]
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. [2008.05]
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. [2008.05]
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. [2008.05]
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. [2008.05]
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. [2008.05]
Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. [2008.05]
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. [2008.04]
Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. [2008.03.01]
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. [2008.02.29]
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. [2008.02]
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. [2008.01.23]
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. [2008.01.22]
Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. [2008.01]
Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model. [2008]
Bioequivalence study of two capsule formulations of omeprazole in healthy volunteers. [2008]
Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. [2008]
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. [2007.12]
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. [2007.12]
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. [2007.12]
Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. [2007.11.01]
|
